![Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/1d37616a-26c8-4db8-aff0-51efc8ee7ac6/gr2_lrg.jpg)
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
![PDF) A blueprint for securing Brazil's marine biodiversity and supporting the achievement of global conservation goals PDF) A blueprint for securing Brazil's marine biodiversity and supporting the achievement of global conservation goals](https://i1.rgstatic.net/publication/345171104_A_blueprint_for_securing_Brazil's_marine_biodiversity_and_supporting_the_achievement_of_global_conservation_goals/links/606ece7f92851c8a7bafb678/largepreview.png)
PDF) A blueprint for securing Brazil's marine biodiversity and supporting the achievement of global conservation goals
![Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial - Annals of Oncology Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/eee30be0-99b8-46fb-86ae-8494048fe0d2/gr1_lrg.jpg)
Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial - Annals of Oncology
![Cannabinoids for the treatment of chronic pruritus: A review - Journal of the American Academy of Dermatology Cannabinoids for the treatment of chronic pruritus: A review - Journal of the American Academy of Dermatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/77fb55e8-f12b-4ff4-952b-345c7d4fccee/gr1_lrg.jpg)
Cannabinoids for the treatment of chronic pruritus: A review - Journal of the American Academy of Dermatology
![Interaction of Hemojuvelin with Neogenin Results in Iron Accumulation in Human Embryonic Kidney 293 Cells* - Journal of Biological Chemistry Interaction of Hemojuvelin with Neogenin Results in Iron Accumulation in Human Embryonic Kidney 293 Cells* - Journal of Biological Chemistry](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/aa5f75b7-0bce-4227-adc8-a207e17da657/gr1.jpg)
Interaction of Hemojuvelin with Neogenin Results in Iron Accumulation in Human Embryonic Kidney 293 Cells* - Journal of Biological Chemistry
![Geochemical and mineralogical characterization of smectites from the Ventzia basin, western Macedonia, Greece | Clay Minerals | Cambridge Core Geochemical and mineralogical characterization of smectites from the Ventzia basin, western Macedonia, Greece | Clay Minerals | Cambridge Core](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20190426110234330-0242:S0009855819000086:S0009855819000086_tab4.gif?pub-status=live)
Geochemical and mineralogical characterization of smectites from the Ventzia basin, western Macedonia, Greece | Clay Minerals | Cambridge Core
![Phosphorylation of ORC2 Protein Dissociates Origin Recognition Complex from Chromatin and Replication Origins* - Journal of Biological Chemistry Phosphorylation of ORC2 Protein Dissociates Origin Recognition Complex from Chromatin and Replication Origins* - Journal of Biological Chemistry](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/df1b4c32-5ad6-43d3-98bf-4f1d617d174b/gr5.jpg)
Phosphorylation of ORC2 Protein Dissociates Origin Recognition Complex from Chromatin and Replication Origins* - Journal of Biological Chemistry
![Geochemical and mineralogical characterization of smectites from the Ventzia basin, western Macedonia, Greece | Clay Minerals | Cambridge Core Geochemical and mineralogical characterization of smectites from the Ventzia basin, western Macedonia, Greece | Clay Minerals | Cambridge Core](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20190426110234330-0242:S0009855819000086:S0009855819000086_tab5.gif?pub-status=live)
Geochemical and mineralogical characterization of smectites from the Ventzia basin, western Macedonia, Greece | Clay Minerals | Cambridge Core
![Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9ae0cdef-2274-4019-99e7-204744c99027/gr3_lrg.jpg)
Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
![Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial - European Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial - European](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/ecf94577-707f-46eb-99b6-3afe8281a1d5/gr1_lrg.jpg)
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial - European
![Editor's Choice – Management of Chronic Venous Disease - European Journal of Vascular and Endovascular Surgery Editor's Choice – Management of Chronic Venous Disease - European Journal of Vascular and Endovascular Surgery](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e5649d3e-1968-4141-8f89-8a6c41c1b3ec/fx3.jpg)